Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Summary

This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, status or response. The study will also investigate how the drugs behave in your body

Timeline

Start

2018-06-18

Primary completion

2020-12-17

Completion

2022-09-06

Drugs

Indications